Synergy Pharmaceuticals posts $14.5 million operating loss for March

By Caroline Salls

Pittsburgh, April 29 – Synergy Pharmaceuticals, Inc. reported a $14.5 million operating loss for March on zero net sales, according to a monthly operating report filed Monday with the U.S. Bankruptcy Court for the Southern District of New York.

Net income for the month was $139.56 million. This figure included a $163.93 million gain related to the sale of assets.

The company had $59.12 million in cash and equivalents as of March 31.

Synergy is a New York-based biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies. The company filed bankruptcy on Dec. 12 under Chapter 11 case number 18-14010.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.